Vigil Neuroscience Completes $90 Million Series B Financing To Advance A Pipeline Of Microglia-Targeted Medicines To Treat Rare And Common Neurodegenerative Diseases
Vigil Neuroscience Completes $90 Million Series B Financing To Advance A Pipeline Of Microglia-Targeted Medicines To Treat Rare And Common Neurodegenerative Diseases
08/18/21, 11:05 AM
Location
cambridgeMoney raised
$90 million
Round Type
series b
Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the completion of a $90 million Series B financing to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration. The financing was led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures and Hatteras Venture Partners as well as new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, Invus, OrbiMed, Rock Springs Capital, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, and Lightstone Ventures.
Company Info
Location
cambridge, maryland, united states
Additional Info
Vigil Neuroscience is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families. www.vigilneuro.com